ArticleRheumatology (Oxford, England)2022
Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus.
Article in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2026Guideline
- Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force.Annals of the rheumatic diseases · 2023Pooled it
- Remission and low disease activity state in childhood-onset systemic lupus erythematosus: differential impact on damage accrual in a Latin American cohort (GLADEL).Lupus science & medicine · 2026Article
- Ethnic Disparities in Achieving Treatment Targets and Organ Damage Accrual in Systemic Lupus Erythematosus: A Multi-Centre Study from Malaysia.Journal of clinical medicine · 2026Article
- Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting-Adjusted Comparison to a Historical Control Group Treated With Belimumab.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Insights into the pathogenesis of childhood-onset SLE in the past decade.Nature reviews. Rheumatology · 2026Review
- Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain.Lupus science & medicine · 2025Article
- Achievement and Features Associated with Childhood Definition of Remission in Juvenile-Onset Systemic Lupus Erythematosus.Turkish archives of pediatrics · 2025Article
- Validation of childhood lupus specific targets: ensuring accurate assessment of disease control in younger, lighter paediatric patients.Rheumatology (Oxford, England) · 2025Article
- Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes.Lupus science & medicine · 2025Article
- Mortality in children and adolescents with autoimmune inflammatory rheumatic diseases admitted to the pediatric intensive care unit.Pediatric rheumatology online journal · 2025Article
- Implementation of the Lupus Low Disease Activity State in Pediatric Rheumatology Care: The Role of the Visual Analog Scale.ACR open rheumatology · 2025Article
- Active implementation of low disease activity state as a treatment endpoint in childhood-onset systemic lupus erythematosus in routine practice is both feasible and associated with better outcomes.Clinical rheumatology · 2024Article
- Childhood-Onset Systemic Lupus Erythematosus (cSLE): An International Perspective.Current allergy and asthma reports · 2024Review
- Revisiting Childhood-Onset Systemic Lupus Erythematosus.Turkish archives of pediatrics · 2024Article
- Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force.Clinical immunology (Orlando, Fla.) · 2024Article
- [Low disease activity and remission status of systemic lupus erythematosus in a real-world study].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?Rheumatology (Oxford, England) · 2024Article
- Long-term outcomes and predictive factors of achieving low disease activity status in childhood systemic lupus erythematosus: a Chinese bicentric retrospective registered study.Frontiers in immunology · 2024Article
- Treat-to-Target in Pediatric Rheumatic Diseases.Current rheumatology reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
objectivesTo assess the achievability and effect of attaining low disease activity (LDA) or remission in childhood-onset SLE (cSLE).
methodsAttainment of three adult-SLE derived definitions of LDA (LLDAS, LA, Toronto-LDA), and four definitions of remission (clinical-SLEDAI-defined remission on/off treatment, pBILAG-defined remission on/off treatment) was assessed in UK JSLE Cohort Study patients longitudinally. Prentice-Williams-Petersen gap recurrent event models assessed the impact of LDA/remission attainment on severe flare/new damage.
resultsLLDAS, LA and Toronto-LDA targets were reached in 67%, 73% and 32% of patients, after a median of 18, 15 or 17 months, respectively. Cumulatively, LLDAS, LA and Toronto-LDA was attained for a median of 23%, 31% and 19% of total follow-up-time, respectively. Remission on-treatment was more common (61% cSLEDAI-defined, 42% pBILAG-defined) than remission off-treatment (31% cSLEDAI-defined, 21% pBILAG-defined). Attainment of all target states, and disease duration (>1 year), significantly reduced the hazard of severe flare (P < 0.001). As cumulative time in each target increased, hazard of severe flare progressively reduced. LLDAS attainment reduced the hazard of severe flare more than LA or Toronto-LDA (P < 0.001). Attainment of LLDAS and all remission definitions led to a statistically comparable reduction in the hazards of severe flare (P > 0.05). Attainment of all targets reduced the hazards of new damage (P < 0.05).
conclusionsThis is the first study demonstrating that adult-SLE-derived definitions of LDA/remission are achievable in cSLE, significantly reducing risk of severe flare/new damage. Of the LDA definitions, LLDAS performed best, leading to a statistically comparable reduction in the hazards of severe flare to attainment of clinical remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.